BTIG raised the firm’s price target on DexCom (DXCM) to $109 from $107 and keeps a Buy rating on the shares after its Q1 results. Revenue topped expectations and a big beat in U.S. sales shows the company is back on track, while its operating expense control offsets gross margin pressures, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: